TEDA Company Wins International Gold Award + EU Patent for Intelligent Blood Transfusion Detection Technology

Recently, the TEDA-based enterprise, Tianjin Dexiang Biotech Co., Ltd., has achieved multiple breakthroughs. Its core technology for microfluidic intelligent blood transfusion detection won gold medals at international invention exhibitions in Serbia and Croatia and received EU patent certification. To date, Dexiang Biotech has secured a total of 68 patent authorizations, including 43 invention patents, with its technology layout covering markets in the United States and the European Union.

Dexiang Biotech was established in 2011 in TEDA West. As a high-tech enterprise in the field of in vitro diagnostics, it integrates R&D, production, and sales and has been recognized as a national "Specialized, Refined, Distinctive, and Innovative" (SRDI) "Little Giant" enterprise and a Chinese hidden "unicorn" company. The company focuses on the development and industrial transformation of in vitro diagnostic technologies, with its core products including column agglutination cards, microfluidic detection cards, and platelet detection kits. In December 2025, Dexiang Biotech’s microfluidic series of anti-human globulin (IgG+C3d) detection cards (microfluidic gel method) successfully obtained approval, marking the official completion of the company’s comprehensive detection system combining reagent, instrument and automated line. These products have been put into trial use in multiple hospitals, demonstrating the company’s capability in rapidly transforming technological R&D into clinical applications. Furthermore, Dexiang Biotech has obtained CE certification for its microfluidic and column agglutination dual-series fully automated blood group analyzers, with key performance indicators reaching leading level globally.